The role of CDK4/6 inhibitors in the treatment of luminal HER2/neu-negative early breast cancer
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have become an integral component of both international and national treatment guidelines for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancer. This review aimed to summarize current evidence on the efficacy of palbociclib, r...